Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The role of parents and caregivers in motivating adolescents with HIV to participate in a long-acting injectable ART clinical trial in South Africa and Uganda.
Makusha T, Namukwaya S, Guga P, Ngubo Z, Xulu Z, Nassanga A, Ngwenya N, Bernays S, Archary M, Ford D, Mutuluuza CK, Kekitiinwa AR, Pett SL, Seeley J; and the LATA Trial Team. Makusha T, et al. Among authors: archary m. AIDS Care. 2026 Feb 26:1-14. doi: 10.1080/09540121.2026.2635483. Online ahead of print. AIDS Care. 2026. PMID: 41744295
Intentions and attitudes of caregivers towards enrolment of their children and adolescents living with HIV into remission trials involving analytic treatment interruption.
Peay HL, Otwombe K, Barnabas S, Barrios-Tascon A, Lain MG, Nhampossa T, Rutebarika D, Jupimai T, Archary M, Maiga AI, Violari A, Spyer MJ, Reddy K, Palma P, Pahwa S, Lichterfeld M, Cotton M, Kuhn L. Peay HL, et al. Among authors: archary m. J Int AIDS Soc. 2026 Feb;29(2):e70084. doi: 10.1002/jia2.70084. J Int AIDS Soc. 2026. PMID: 41664887 Free PMC article.
Interactive Transition Support for Adolescents Living with HIV Comparing Virtual and In-person delivery (InTSHA VIP): a stepped-wedge, cluster-randomised trial in South Africa.
Magut F, Baisley K, Sibaya T, Upton J, Khoza T, Gethers CT, Marconi VC, Sewnarain L, Haberer JE, Shahmanesh M, Archary M, Zanoni BC. Magut F, et al. Among authors: archary m. BMC Health Serv Res. 2026 Jan 30;26(1):295. doi: 10.1186/s12913-026-14070-8. BMC Health Serv Res. 2026. PMID: 41618237 Free PMC article.
Severe, primary, and incidental COVID-19 in hospitalised children, South Africa: 2020-2023.
Goga A, Ramraj T, Cloete J, Mawela D, Waggie Z, Archary M, Chinniah K, Jeena P, Tabane NE, Van Zyl R, Reubenson G, Strehlau R, Feucht U, Reddy T, Mchunu N, Cawood S, Zühlke L, Webb K, Zar HJ, Donald KA, Scott C, Morrow BM, Aldersley T, du Plessis NM, Chetty T, Velaphi S, Dangor Z, Moore DP. Goga A, et al. Among authors: archary m. J Glob Health. 2026 Jan 30;16:04009. doi: 10.7189/jogh.16.04009. J Glob Health. 2026. PMID: 41614559 Free PMC article.
Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trial.
Turkova A, White E, Violari A, Mujuru HA, Kekitiinwa AR, Lugemwa A, Kaudha E, Na-Rajsima S, Ahimbisibwe GM, Variavae E, Archary M, Akhalwaya Y, Puthanakit T, Bwakura-Dangarembizi M, Bbuye D, Kasozi M, Liberty A, Königs C, Welch SB, Riault Y, Bamford A, Cressey TR, Musoke P, Kityo C, Ferrand R, Giaquinto C, Rojo P, Gibb DM, Ford D; ODYSSEY trial team. Turkova A, et al. Among authors: archary m. Lancet Child Adolesc Health. 2026 Mar;10(3):189-202. doi: 10.1016/S2352-4642(25)00339-6. Epub 2026 Jan 21. Lancet Child Adolesc Health. 2026. PMID: 41579881 Free article. Clinical Trial.
Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa.
Anena D, Chappell E, Nazzinda R, Kiilu C, Chitsamatanga M, Arumugam T, Green A, Kityo Mutuluuza C, Bwakura-Dangarembizi M, Siika A, Archary M, Jafta L, Namukwaya S, Seeley J, Akabwai G, Mugerwa H, Bevers L, Burger D, Walker S, Bamford A, South A, Apoto N, Bush M, Thomason MJ, Spittle B, Ford D, Kekitiinwa AR, Pett SL; LATA Trial Team. Anena D, et al. Among authors: archary m. Contemp Clin Trials. 2026 Mar;162:108213. doi: 10.1016/j.cct.2025.108213. Epub 2026 Jan 7. Contemp Clin Trials. 2026. PMID: 41512916 Free article.
Dolutegravir in neonates: finally we are getting there!
Naidoo KL, Archary M. Naidoo KL, et al. Among authors: archary m. Lancet HIV. 2025 Nov;12(11):e739-e740. doi: 10.1016/S2352-3018(25)00274-7. Epub 2025 Oct 8. Lancet HIV. 2025. PMID: 41075811 No abstract available.
Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial.
Bevers LAH, Toledo G, Kisekka M, Kaudha E, Ahimbisibwe GM, Deprez I, Arumugan T, Variava E, Violari A, White I, Bbuye D, Nanduudu A, Mulwanyi E, Amuge P, Rutebarika DA, Kekitiinwa A, Kityo C, Musoke P, Archary M, Boles J, Thomason MJ, de Wildt SN, Giaquinto C, Colbers A, Burger DM, Buchanan AM, Chan MK, Jacobs TG, Turkova A; D3 TRIAL TEAM. Bevers LAH, et al. Among authors: archary m. EBioMedicine. 2025 Oct;120:105929. doi: 10.1016/j.ebiom.2025.105929. Epub 2025 Sep 26. EBioMedicine. 2025. PMID: 41014973 Free PMC article. Clinical Trial.
131 results